Paradigm Initiates Genomic Profiling for Pharmatech’s AccessPPM Cancer Registry Program
Novel clinical trial matching protocol enables greater access to genomic profiling and targeted clinical studies for cancer patients nationwide.
ANN ARBOR, Mich. and DENVER, Aug. 5, 2014 /PRNewswire-USNewswire/ — Paradigm has announced today they have initiated genomic testing for Pharmatech’s AccessPPM Cancer Registry.
Pharmatech’s AccessPPM is a cancer registry designed to collect EMR data and genomic information to help best match cancer patients with targeted clinical trials. The AccessPPM program and associated protocol currently includes 55 sites and is quickly poised to expand to Pharmatech’s entire research network of 345 cancer centers.
“We are truly pleased to begin providing our genomic profiling services for the patients served by AccessPPM,” noted Dr. Robert Penny, CEO of Paradigm. “Our ability to provide clinical grade sequencing through our PCDx test to physician clients in 4-5 business days ensures that continuity of care is maintained and that patients are quickly and efficiently matched to the appropriate therapies and clinical trials. “We anticipate that Pharmatech’s network of sites and cancer centers will be of strategic value to the long-term growth and expansion.”
Rob Bohacs, CEO of Pharmatech, noted, “This is a great milestone as we begin ramping the AccessPPM program. We believe AccessPPM will change the way today’s oncology patient accesses clinical trials and will help pharmaceutical companies identify patients that are truly interested in research.” “Our relationship with Paradigm is a logical and natural fit for this program.”
Paradigm is a non-profit molecular information corporation established to bring cutting-edge diagnostics to cancer patients and clinical trials by providing information about the genomic makeup of the patient’s cancer and potential therapies based on the specific characterization of the patient’s tumor that can impact the patient’s course of treatment. Paradigm’s Next-Generation Sequencing based diagnostic test PCDx provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market. For more information visit www.paradigmdx.org.
Pharmatech, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) with a focus on oncology clinical research. Through an organized network of cancer clinics, the Company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and on promoting cancer patient care through the inclusion of clinical trials in a spectrum of patient treatment options.